FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041978414> ?p ?o ?g. }

• W3041978414 endingPage "3213" @default.
• W3041978414 startingPage "3202" @default.
• W3041978414 abstract "The scientific rationale for selection of the surfactant type during oral formulation development requires an in-depth understanding of the interplay between surfactant characteristics and biopharmaceutical factors. Currently, however, there is a lack of comprehensive knowledge of how surfactant properties, such as hydrophilic-lipophilic balance (HLB), digestibility, and fatty acid (FA) chain length, translate into in vivo performance. In the present study, the relationship between surfactant properties, in vitro characteristics, and in vivo bioavailability was systematically evaluated. An in vitro lipolysis model was used to study the digestibility of a variety of nonionic surfactants. Eight surfactants and one surfactant mixture were selected for further analysis using the model poorly water-soluble drug nilotinib. In vitro lipolysis of all nilotinib formulations was performed, followed by an in vivo pharmacokinetic evaluation in rats. The in vitro lipolysis studies showed that medium-chain FA-based surfactants were more readily digested compared to long-chain surfactants. The in vivo study demonstrated that a Tween 20 formulation significantly enhanced the absolute bioavailability of nilotinib up to 5.2-fold relative to an aqueous suspension. In general, surfactants that were highly digestible in vitro tended to display higher bioavailability of nilotinib in vivo. The bioavailability may additionally be related to the FA chain length of digestible surfactants with an improved exposure in the case of medium-chain FA-based surfactants. There was no apparent relationship between the HLB value of surfactants and the in vivo bioavailability of nilotinib. The impact of this study's findings suggests that when designing surfactant-based formulations to enhance oral bioavailability of the poorly water-soluble drug nilotinib, highly digestible, medium chain-based surfactants are preferred. Additionally, for low-permeability drugs such as nilotinib, which is subject to efflux by intestinal P-glycoprotein, the biopharmaceutical effects of surfactants merit further consideration." @default.
• W3041978414 created "2020-07-16" @default.
• W3041978414 creator A5000845292 @default.
• W3041978414 creator A5006080071 @default.
• W3041978414 creator A5066108747 @default.
• W3041978414 creator A5066208508 @default.
• W3041978414 creator A5067939292 @default.
• W3041978414 date "2020-07-10" @default.
• W3041978414 modified "2023-10-10" @default.
• W3041978414 title "Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib" @default.
• W3041978414 cites W134089957 @default.
• W3041978414 cites W1979049827 @default.
• W3041978414 cites W1991916654 @default.
• W3041978414 cites W1994505523 @default.
• W3041978414 cites W2001807364 @default.
• W3041978414 cites W2017730149 @default.
• W3041978414 cites W2020626055 @default.
• W3041978414 cites W2021743876 @default.
• W3041978414 cites W2026883693 @default.
• W3041978414 cites W2032716251 @default.
• W3041978414 cites W2033305262 @default.
• W3041978414 cites W2036181656 @default.
• W3041978414 cites W2037075389 @default.
• W3041978414 cites W2038306416 @default.
• W3041978414 cites W2040291220 @default.
• W3041978414 cites W2041804703 @default.
• W3041978414 cites W2044148793 @default.
• W3041978414 cites W2046336496 @default.
• W3041978414 cites W2051311750 @default.
• W3041978414 cites W2055312350 @default.
• W3041978414 cites W2055576047 @default.
• W3041978414 cites W2056995570 @default.
• W3041978414 cites W2067954654 @default.
• W3041978414 cites W2069235788 @default.
• W3041978414 cites W2069506489 @default.
• W3041978414 cites W2071215562 @default.
• W3041978414 cites W2072175601 @default.
• W3041978414 cites W2074907330 @default.
• W3041978414 cites W2076628780 @default.
• W3041978414 cites W2078964293 @default.
• W3041978414 cites W2084053737 @default.
• W3041978414 cites W2085197817 @default.
• W3041978414 cites W2085535677 @default.
• W3041978414 cites W2086423811 @default.
• W3041978414 cites W2089826626 @default.
• W3041978414 cites W2101223910 @default.
• W3041978414 cites W2117577270 @default.
• W3041978414 cites W2119280206 @default.
• W3041978414 cites W2120350838 @default.
• W3041978414 cites W2129207762 @default.
• W3041978414 cites W2139910235 @default.
• W3041978414 cites W2144151374 @default.
• W3041978414 cites W2144262303 @default.
• W3041978414 cites W2202134586 @default.
• W3041978414 cites W2316986094 @default.
• W3041978414 cites W2317033060 @default.
• W3041978414 cites W2328474694 @default.
• W3041978414 cites W2329755406 @default.
• W3041978414 cites W2333000505 @default.
• W3041978414 cites W2334259539 @default.
• W3041978414 cites W2339649458 @default.
• W3041978414 cites W2490387705 @default.
• W3041978414 cites W2493494453 @default.
• W3041978414 cites W2510550345 @default.
• W3041978414 cites W2511328803 @default.
• W3041978414 cites W2580145600 @default.
• W3041978414 cites W2602404657 @default.
• W3041978414 cites W2768738643 @default.
• W3041978414 cites W2778756086 @default.
• W3041978414 cites W2890360281 @default.
• W3041978414 cites W2898046326 @default.
• W3041978414 cites W2909432337 @default.
• W3041978414 cites W2915569538 @default.
• W3041978414 cites W2946182267 @default.
• W3041978414 cites W2955461563 @default.
• W3041978414 cites W2990381382 @default.
• W3041978414 cites W3002077806 @default.
• W3041978414 cites W3032974176 @default.
• W3041978414 doi "https://doi.org/10.1021/acs.molpharmaceut.0c00305" @default.
• W3041978414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32649208" @default.
• W3041978414 hasPublicationYear "2020" @default.
• W3041978414 type Work @default.
• W3041978414 sameAs 3041978414 @default.
• W3041978414 citedByCount "20" @default.
• W3041978414 countsByYear W30419784142020 @default.
• W3041978414 countsByYear W30419784142021 @default.
• W3041978414 countsByYear W30419784142022 @default.
• W3041978414 countsByYear W30419784142023 @default.
• W3041978414 crossrefType "journal-article" @default.
• W3041978414 hasAuthorship W3041978414A5000845292 @default.
• W3041978414 hasAuthorship W3041978414A5006080071 @default.
• W3041978414 hasAuthorship W3041978414A5066108747 @default.
• W3041978414 hasAuthorship W3041978414A5066208508 @default.
• W3041978414 hasAuthorship W3041978414A5067939292 @default.
• W3041978414 hasConcept C112705442 @default.
• W3041978414 hasConcept C140985366 @default.
• W3041978414 hasConcept C150903083 @default.
• W3041978414 hasConcept C171089720 @default.

• next